Who gets to be a patient?
If psychedelic therapy becomes a real treatment, the next question is not whether it works but who will be able to reach it — and whether access will follow need or money.
Suppose the optimistic version comes true and one or more psychedelic therapies are approved for serious, hard-to-treat conditions. A quieter question immediately follows the celebratory one: who, in practice, will actually be able to receive them?
A labour-intensive treatment is an access problem
These are not pills you collect from a pharmacy. The model under study involves trained clinicians, long preparation, supervised dosing, and integration over weeks. That is expensive and slow by design. Left to the market alone, a treatment with those properties tends to reach the affluent and well-connected first, and everyone else much later, if at all.
A therapy that only the comfortable can afford does not reduce suffering. It redistributes it upward.
The pattern we have seen before
New psychiatric treatments have a history of arriving unevenly — concentrated in wealthy areas, under-available to the communities carrying the heaviest burden of untreated illness. There is no law of nature that says this must repeat. But it will repeat by default unless access is designed for deliberately.
What designing for access looks like
- Training pathways that do not restrict this work to a small, costly elite.
- Coverage decisions that consider need, not only ability to pay.
- Research populations that resemble the people who will eventually need care, so the evidence actually generalises to them.
The scientific question — does it work? — is being taken seriously. The distributive question — for whom? — deserves the same seriousness, and it has to be asked now, while the answers can still be shaped.